Skip to main content
. Author manuscript; available in PMC: 2016 Jun 13.
Published in final edited form as: Sci Transl Med. 2012 Apr 25;4(131):131ra51. doi: 10.1126/scitranslmed.3003501

Fig. 5.

Fig. 5

Effect of GRN-529 on open field locomotion at doses that reversed repetitive and social deficits. Exploratory locomotion was assayed in a standard automated open field arena, in 5-min time bins across a 30-min session after the identical GRN-529 treatments. (A) B6 displayed a significant increase in total distance traversed after GRN-529 at the highest dose, 3.0 mg/kg, intraperitoneally, compared to vehicle. (B and C) GRN-529 administration had no significant effect on (B) time spent in the center of the arena or (C) vertical activity in B6 tested at NIMH. n = 9 to 10 per dose. (D) BTBR displayed significant increases in total distance traversed after GRN-529 at doses of 1.0 and 3.0 mg/kg intraperitoneally compared to vehicle, indicating increased exploratory activity. (E and F) GRN-529 administration had no significant effect on (E) time spent in the center of the arena or (F) vertical activity in BTBR. *P < 0.05, n = 10 per dose, cohort 1 tested at NIMH. See fig. S4 for open field results replicated at NIMH and fig. S5 for open field results replicated at Pfizer. See fig. S6 for additional open field parameters in C58 mice.